重要内容提示： 回购注销原因：北京昭衍新药研究中心股份有限公司（以下简称"公司"） 已终止实施2021年及2022年A股员工持股计划，公司拟注销回购专用账户中的A 股共计129,114股。 本次注销股份的有相关情况： 证券代码：603127 证券简称：昭衍新药 公告编号：2026-001 北京昭衍新药研究中心股份有限公司 关于员工持股计划回购股份注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 由于2021年员工持股计划拟参与对象尚未出资认购，该员工持股计划尚未成 立。2023年3月30日，公司召开了第四届董事会第二次会议及第四届监事会第二 次会议，审议通过《关于终止实施2021年A股员工持股计划的议案》。具体内容 详见公司于2023年3月31日在上海证券交易所网站（www.sse.com.cn）及公司指 定信息披露媒体《上海证券报》披露的《昭衍新药关于终止实施2021年A股员工 持股计划的公告》（公告编号：2023-013）。 （二）2022年A股员工持股计划 公司于2022年8月15日召开第三届董事会第三 ...

截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 FF301 由於北京昭衍新藥研究中心股份有限公司(「本公司」)是於中華人民共和國註冊成立，因此" 法定股本"之概念不適用於本公司。第 I 部分所載資料是指本公司的"已發行股本"。 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 ...

Group 1 - The CRO (Contract Research Organization) sector stocks are showing strong performance, with notable increases in share prices [1] - Zhaoyan New Drug (06127.HK) has risen by 11.52%, reaching HKD 22.26 [1] - Tigermed (03347.HK) has increased by 5.98%, now priced at HKD 44.98 [1] - WuXi AppTec (02359.HK) has gained 4.65%, with shares at HKD 105.7 [1] - Kanglong Chemical (03759.HK) has seen a rise of 4.59%, trading at HKD 20.74 [1]

截至发稿，昭衍新药(06127.HK)涨9.72%、泰格医药(03347.HK)涨5.94%、康龙化成(03759.HK)涨 3.68%。 本文源自：金融界AI电报 ...

Company Dynamics - Zhou Zhiwen, a major shareholder and actual controller of Zhaoyan New Drug (603127.SH), has announced a significant share reduction plan, potentially cashing out over 500 million yuan based on the current stock price [2] - Before the reduction, Zhou held 74,725,981 shares, accounting for 9.9704% of the total share capital, with a combined holding of 32.274% with his spouse, Feng Yuxia [2] - Following the announcement of the share reduction, Zhaoyan New Drug's stock dropped by 6.20% on December 30, closing at 34.80 yuan, indicating a potential cash-out of over 500 million yuan from the sale of 14.98 million shares [2] Industry Insights - Zhaoyan New Drug specializes in non-clinical research services, clinical services, and the supply of experimental models, gaining prominence in the capital market due to its assets in experimental monkeys [2] - The average market price of experimental monkeys has seen significant fluctuations, with prices rising from 13,800 yuan per monkey in 2017 to nearly 190,000 yuan in 2022, before experiencing a decline in 2023 [2][3] - In November 2023, the price of experimental monkeys dropped to approximately 113,000 yuan each, reflecting a decrease of over 30% from the peak [3] - Despite a decline in revenue by 26.23% year-on-year to 985 million yuan in the first three quarters of 2025, Zhaoyan New Drug managed to achieve a net profit of 80.71 million yuan, indicating a recovery in performance [3] - As of December 29, 2025, Zhaoyan New Drug's stock price has increased by over 120% within the year [3] Shareholder Activity - Zhou Zhiwen has a history of share reductions, having sold a total of 14.11 million shares since November 2020, resulting in approximately 915 million yuan in cash [4]

Core Viewpoint - The stock price of Zhaoyan New Drug (603127.SH) surged due to the rebound in the market price of experimental monkeys, prompting major shareholder Zhou Zhiwen to announce a significant share reduction plan, potentially cashing out over 500 million yuan [1] Group 1: Shareholder Actions - Zhou Zhiwen plans to reduce his holdings by up to 14,980,000 shares, representing 20.0466% of his holdings and 1.99873% of the company's total share capital, within three months after the announcement [1] - Prior to the reduction, Zhou Zhiwen held 74,725,981 shares, accounting for 9.9704% of the company, with the couple's total holding at 32.274% [1] - Following the announcement of the share reduction, Zhaoyan New Drug's stock fell by 6.20% to a closing price of 34.80 yuan [1] Group 2: Company Overview - Zhaoyan New Drug specializes in non-clinical research services, clinical services, and the supply of experimental models, with a notable focus on experimental monkeys, which are critical for various research fields [2] - The price of experimental monkeys has fluctuated significantly, with the average market price rising from 13,800 yuan in 2017 to nearly 190,000 yuan in 2022, before experiencing a decline in 2023 [2][3] Group 3: Financial Performance - In Q1 2024, Zhaoyan New Drug reported a revenue of 325 million yuan, a year-on-year decrease of 12.07%, and a net loss of 272 million yuan, attributed to a 284 million yuan loss from changes in the fair value of biological assets [3] - By the first three quarters of 2025, the company achieved a revenue of 985 million yuan, a year-on-year decrease of 26.23%, but turned a profit with a net income of 80.71 million yuan [3] - The stock price of Zhaoyan New Drug increased by over 120% throughout the year, reflecting a recovery in the market price of experimental monkeys [3] Group 4: Market Perception - Some market analysts argue that Zhaoyan New Drug primarily sells experimental services rather than monkeys, suggesting that monkey prices do not directly reflect the company's sustainable profitability [4] - Despite this, fluctuations in the value of experimental monkeys significantly impact the company's financial performance, leading to potential distortions in financial reporting [4]

证券之星消息，12月30日医疗服务板块较上一交易日下跌0.73%，昭衍新药领跌。当日上证指数报收于 3965.12，下跌0.0%。深证成指报收于13604.07，上涨0.49%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 920670 | 数字人 | 15.87 | 4.20% | 5.91万 | 9396.08万 | | 600568 | ST中珠 | 2.52 | 2.86% | 22.48万 | 5686.21万 | | 300347 | 泰格医药 | 56.63 | 1.27% | 9.14万 | 5.16亿 | | 688621 | 阳光诺和 | 64.18 | 1.20% | 1.74万 | 1.10亿 | | 688131 | 皓元医药 | 72.54 | 0.96% | 2.24万 | 1.62亿 | | 301096 | 百诚医药 | 57.75 | 0.70% | 3.10万 | 1.78亿 | | 300363 | 博腾股份 | 23.45 ...

中国经济网北京12月30日讯 昭衍新药（603127）(603127.SH)昨晚发布关于股东减持股份计划公告。 截至公告披露日，公司实际控制人之一周志文持有公司股票74,725,981股，占公司总股本9.9704%，其持有的股份来 源于首发前限售股份及公司资本公积金转增股份等。 周志文拟自减持计划公告之日起15个交易日后的3个月内通过上海证券交易所以集中竞价或大宗交易的方式减持不超 过14,980,000股,不超过其持有股份的20.0466%，不超过公司总股本的1.99873%。减持计划实施期间，公司若发生送 红股、转增股本、增发新股或配股等股本除权事项的，减持数量将进行相应调整。减持价格依据市场价格确定。 按照12月29日收盘价37.1元测算，周志文套现金额约合5.56亿元。 昭衍新药2024年年度报告显示，公司实际控制人是冯宇霞（女）、周志文（男）夫妇。 昭衍新药表示，本次减持计划是股东根据自身资金需要进行的减持，本次减持不会对公司治理结构及持续经营情况 产生重大影响。在减持期间内，股东将根据市场情况、公司股价及有关规则所允许的可交易窗口期间等因素选择是 否实施本计划，因此减持时间、减持价格、减持数量存在 ...

每经AI快讯，昭衍新药(06127.HK)跌超6%，截至发稿跌6.25%，报19.8港元，成交额8459.44万港元。 （文章来源：每日经济新闻） ...